Selskabsmeddelelse30.9.2024, 12.30Bulletin from the extraordinary general meeting of Calliditas Therapeutics AB (publ)
Selskabsmeddelelse16.9.2024, 13.30Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm
Selskabsmeddelelse3.9.2024, 10.15Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei
Selskabsmeddelelse3.9.2024, 10.00Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)
Selskabsmeddelelse13.8.2024, 05.00Calliditas Therapeutics: Calliditas Interim Report January to June 2024
Pressemeddelelse5.8.2024, 05.00Calliditas Therapeutics: Invitation to the presentation of Calliditas's interim report January - June 2024
Pressemeddelelse26.7.2024, 15.00Calliditas Therapeutics: Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy
Selskabsmeddelelse26.7.2024, 06.00Calliditas Therapeutics: Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis
Pressemeddelelse4.7.2024, 06.30Calliditas Therapeutics: Launch of Phase 3 clinical trial with Nefecon in Japan
Selskabsmeddelelse17.6.2024, 15.30Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
Selskabsmeddelelse30.5.2024, 18.00Calliditas Therapeutics: Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo[®] for the treatment of IgA nephropathy
Pressemeddelelse28.5.2024, 12.00Calliditas Therapeutics Presents Data at the 61[st] European Renal Association Congress
Selskabsmeddelelse28.5.2024, 06.30Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation